Portfolio

Sparrow

CEO and President Robert Jacks

Targeted cardiometabolic therapeutics

Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company delivering improved outcomes for patients who struggle to control diabetes and related metabolic conditions with current options.

The company’s lead candidate, clofutriben, is a first-in-class, once-daily, oral HSD-1 inhibitor initially in development for the millions of patients with type 2 diabetes and elevated cortisol. HSD-1 inhibition complements existing antidiabetic agents by addressing a cause of disease progression and treatment resistance across a spectrum of metabolic dysfunction. Clofutriben has been associated with improved glycemic control while generally safe and well tolerated in multiple clinical trials without requiring dose titration.

Human Health

Sparrow

US

1050 SW 6th Avenue
Suite 1100
Portland, OR 97204

Industry

Biotech

Status

Current

Location

United States